---

---

tags : Results    entities : Abbvie inc.   

save search

---

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 1.52% | O: 0.75% H: 0.0% C: 0.0%
rinvoq positive cell results study

---

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M |

n/a

| -13.2% | O: -1.58% H: 1.87% C: 0.53%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -4.93% | O: -0.03% H: 0.0% C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| -6.62% | O: -0.89% H: 0.0% C: 0.0%
KMDA | News | $5.05 -0.98% -0.99% 27K |

Health Technology

| -11.58% | O: 0.68% H: 0.0% C: -1.86%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| -1.51% | O: 0.58% H: 1.2% C: 0.84%
business year update financial results

---

I-Mab Reports Full Year 2023 Financial Results and Business Update
Published: 2024-03-14 (Crawled : 21:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| -7.71% | O: -0.07% H: 0.0% C: 0.0%
TCON | $1.97 -6.64% -7.11% 240K |

Health Technology

| 347.9% | O: -6.31% H: 4.85% C: -8.54%
IMAB | $1.81 0.56% 0.55% 340K |

Health Technology

| 0.0% | O: -5.56% H: 9.41% C: 9.41%
business year update financial results

---

AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
Published: 2024-02-02 (Crawled : 14:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 1.71% | O: 3.59% H: 0.0% C: 0.0%
abbvie financial results

---

Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
Published: 2024-01-08 (Crawled : 13:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 3.03% | O: 0.52% H: 0.0% C: 0.0%
positive program trial results

---

AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-11-29 (Crawled : 14:30) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 19.69% | O: -0.73% H: 0.78% C: 0.35%
lung abbvie positive cancer cell topline trial results

---

CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
Published: 2023-11-29 (Crawled : 12:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 19.69% | O: -0.73% H: 0.78% C: 0.35%
CLGN | $5.22 -2.54% 1.2K |

Health Technology

| -9.25% | O: -3.32% H: 4.15% C: -3.43%
biotechnologies financial results

---

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update
Published: 2023-11-28 (Crawled : 21:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M |

n/a

| 34.9% | O: 1.02% H: 0.0% C: -5.05%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| -2.72% | O: 0.18% H: 0.12% C: -0.16%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -2.31% | O: -0.04% H: 0.0% C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 19.69% | O: -0.73% H: 0.78% C: 0.35%
KMDA | News | $5.05 -0.98% -0.99% 27K |

Health Technology

| 8.46% | O: 0.73% H: 0.0% C: -1.04%
business update financial results

---

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
Published: 2023-11-28 (Crawled : 21:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M |

n/a

| 34.9% | O: 1.02% H: 0.0% C: -5.05%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -2.31% | O: -0.04% H: 0.0% C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 19.69% | O: -0.73% H: 0.78% C: 0.35%
KMDA | News | $5.05 -0.98% -0.99% 27K |

Health Technology

| 8.46% | O: 0.73% H: 0.0% C: -1.04%
business update financial results

---

Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
Published: 2023-11-09 (Crawled : 13:30) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 15.88% | O: -1.81% H: 0.43% C: -2.1%
IRWD | $7.94 4.47% 4.28% 2.5M |

Health Technology

| -14.19% | O: 2.93% H: 4.37% C: 0.21%
pharmaceuticals ironwood results

---

Genmab Announces Financial Results for the First Nine Months of 2023
Published: 2023-11-07 (Crawled : 16:00) - globenewswire.com
GNMSF | $290.38 3.83% 220 |

Health Technology

| -0.26% | O: 0.39% H: 4.92% C: 1.52%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 0.97% | O: 0.24% H: 0.18% C: 0.16%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -2.48% | O: 0.18% H: 0.0% C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 17.36% | O: -0.28% H: 0.0% C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K |

Health Technology

| -0.52% | O: 0.24% H: 3.44% C: 2.07%
BNTX | $86.82 0.75% 0.75% 1.6M |

Health Technology

| -12.94% | O: -0.35% H: 3.09% C: 3.03%
financial results

---

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published: 2023-11-07 (Crawled : 15:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 17.36% | O: -0.28% H: 0.0% C: 0.0%
SMMT A | $3.51 0.0% 1.7M |

Health Technology

| 60.55% | O: -0.46% H: 6.68% C: -11.75%
PLSE | $7.2 -2.17% -2.22% 180K |

Health Technology

| 38.54% | O: 0.39% H: 6.43% C: 1.92%
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -21.82% | O: -0.82% H: 0.73% C: -0.4%
ALNY | $144.315 -0.58% -0.59% 700K |

Health Technology

| -13.6% | O: 1.06% H: 2.42% C: 0.76%
therapeutics financial results

---

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 17.36% | O: -0.28% H: 0.0% C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M |

Health Technology

| -41.53% | O: -22.6% H: 3.28% C: -9.85%
business financial results

---

Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024
Published: 2023-10-28 (Crawled : 12:20) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| Email alert Add to watchlist
fy2024 pharma results

---

AbbVie Reports Third-Quarter 2023 Financial Results
Published: 2023-10-27 (Crawled : 20:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 15.11% | O: -4.81% H: 0.0% C: 0.0%
abbvie financial results

---

Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
Published: 2023-10-24 (Crawled : 13:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 14.98% | O: 0.3% H: 0.0% C: 0.0%
positive treatment topline results

---

Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
Published: 2023-10-04 (Crawled : 15:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 12.58% | O: -0.89% H: 0.0% C: 0.0%
cls-484 cancer preclinical immunotherapy potential results

---

Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
Published: 2023-08-30 (Crawled : 20:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M |

n/a

| 35.87% | O: 0.21% H: 3.28% C: 1.54%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -10.68% | O: -1.35% H: 0.12% C: -1.03%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 12.29% | O: 0.16% H: 0.0% C: 0.0%
KMDA | News | $5.05 -0.98% -0.99% 27K |

Health Technology

| -7.82% | O: 1.24% H: 1.23% C: 0.88%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| 4.28% | O: 0.13% H: 0.3% C: -0.73%
six business update financial results

---

Piramal Pharma Limited Announces Consolidated Results for Q1FY24
Published: 2023-08-03 (Crawled : 23:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 11.65% | O: -0.05% H: 1.07% C: -0.83%
fy24 pharma results

---

Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
Published: 2023-08-03 (Crawled : 20:00) - globenewswire.com
SGHT | $5.14 -1.91% -1.95% 130K |

| -36.19% | O: 0.62% H: 10.26% C: 6.92%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 11.65% | O: -0.05% H: 1.07% C: -0.83%
year sciences financial results

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---